China CDC Weekly · 2023 · 102 citations · 6 references
Veterinary MedicineInfectious DiseasesPreventive MedicineImmunizationInfection PreventionVaccinologyVaccinationVaccine DevelopmentVaccine EffectivenessVaccine EfficacyVaccine SafetyVaccine-preventable DiseasesCoronavirus Infection PreventionCoronavirus VaccinesEffectiveness Against Symptomatic DiseaseEfficacy Against InfectionHuman VaccinationOverall Vaccine EffectivenessPopulation-based Vaccine EffectivenessSars-cov-2 Infection
What is already known about this topic?: A considerable percentage of the population has received both primary and booster vaccinations, which could potentially provide protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron infections and related symptoms. What is added by this report?: The self-reported infection rate, as determined from an online survey, reached its peak (15.5%) between December 19 and 21, 2022, with an estimated 82.4% of individuals in China being infected as of February 7, 2023. During the epidemic, the effectiveness of booster vaccinations against SARS-CoV-2 Omicron infection was found to be 49.0% within three months of vaccination and 37.9% between 3 and 6 months following vaccination. Furthermore, the vaccine effectiveness of the booster vaccination in relation to symptom prevention varied from 48.7% to 83.2% within three months and from 25.9% to 69.0% between 3 and 6 months post-booster vaccination. What are the implications for public health practice?: The development and production of efficacious vaccines, together with prompt vaccinations or emergency vaccinations, have the potential to mitigate the epidemic's impact and safeguard public health.
6